2|0|Public
50|$|On July 31, 2008, Sanofi-Aventis {{announced}} that it has decided to discontinue development of <b>amibegron.</b>|$|E
50|$|<b>Amibegron</b> (SR-58,611A) {{was a drug}} {{developed}} by Sanofi-Aventis (now Sanofi) which acts as a selective agonist for the β3 adrenergic receptor. It is the first orally active β3 agonist developed {{that is capable of}} entering the central nervous system, and has antidepressant and anxiolytic effects.|$|E

